PolarityBio SkinTE Phase 3 trial wins top SAWC abstract award
PolarityBio has received the Highest Scoring Abstract Award in the Clinical Research category at the Symposium on Advanced Wound Care (SAWC) Fall 2026, held in Las Vegas last week, for its pivotal Phase 3 study of SkinTE in non-healing diabetic foot ulcers. The recognition follows a First-to-Podium presentation at the same conference where the company reported that the COVER DFUS II trial met its primary efficacy endpoint of complete wound closure within 12 weeks.
Study Chair Robert S. Kirsner, MD, PhD, who presented the topline data on 16 October, described the autologous multicellular approach as offering meaningful benefit to patients with chronic, non-healing diabetic foot ulcers. Full trial data, including subgroup analyses, will be withheld until peer-reviewed publication to protect journal publication rights, the company said.
Trial design and regulatory position
COVER DFUS II (NCT06140303) is a randomised controlled trial that enrolled 120 patients across multiple US sites over 14 months, randomised 1:1 to SkinTE plus standard of care or standard of care alone. Participants were required to have a wound persisting for at least four weeks and were excluded from randomisation if their wound shrank by more than 30% during a two-week standard-of-care run-in period, a design feature intended to enrich the population for true non-healers.
The Salt Lake City company filed a Biologics Licence Application (BLA) for SkinTE, and the FDA accepted it for Priority Review in September 2026, setting a PDUFA target action date of 16 March 2027. SkinTE carries both Regenerative Medicine Advanced Therapy (RMAT) and Breakthrough Therapy designations for the Wagner Grade 1 DFU indication. Nikolai Sopko, MD, PhD, President, Chief Operating Officer and Chief Scientific Officer, said the conference recognition represented "exciting momentum" following those regulatory milestones.
Market context and competitive landscape
Diabetic foot ulcers affect an estimated 15–25% of people with diabetes over their lifetime and represent a substantial unmet need, with standard wound-care products and negative-pressure wound therapy delivering incomplete healing rates in a large proportion of patients. The advanced wound-care biologics market has attracted a number of competing platforms, including acellular dermal matrices, growth-factor therapies, and other cell-based constructs, several of which carry FDA clearances or approvals.
SkinTE's autologous, multicellular approach differentiates it from allogenic or acellular products, though autologous cell therapies typically carry higher manufacturing and logistical complexity. The RMAT designation reflects the FDA's view of SkinTE as a regenerative medicine product with preliminary clinical evidence; historically, RMAT products have benefited from earlier and more intensive FDA interaction during development, though the designation alone does not guarantee approval.
Beyond diabetic foot ulcers, PolarityBio is advancing SkinTE for venous leg ulcers and pressure injuries, indications that would substantially expand the addressable market if further trials succeed. Investors and clinicians will be watching the peer-reviewed publication closely for the headline closure rate, confidence intervals, and any durability data from the 24-week follow-up period before forming a full view of SkinTE's competitive positioning ahead of the March 2027 PDUFA date.